Ascendis Pharma (ASND): Three New Drugs Are Turning This Biotech Into A Growth Machine

Ascendis Pharma (ASND) has seen a surge in growth following the introduction of three new drugs. In their second-quarter report, the biotech company announced that total product revenue had nearly doubled to €315 million compared to the previous year. All three of the company's approved TransCon therapies – SKYTROFA, YORVIPATH, and YUVIWEL – began generating meaningful sales in the same quarter for the first time.

YORVIPATH, a treatment for hypoparathyroidism, reached €252 million in the quarter and has become a blockbuster drug just two years after its U.S. launch. YUVIWEL, the newest addition, brought in €8 million in its first quarter on the market and has already enrolled more than 220 patients, with 65% already approved for reimbursement.

The company's strong financial position, with €812 million in cash and no bank or convertible debt, allows it to fund these launches without external financing. Although reported operating profit included a €158 million gain from a previous sale, non-IFRS profit reached €92 million, reflecting a 27% margin. Despite this impressive growth, the company faces challenges such as rising costs and the uncertain regulatory timelines for YUVIWEL's full approval.

The stock trades at a forward price-to-earnings ratio of 15.92, which may not be justified by the growth rate YORVIPATH and YUVIWEL are currently achieving.